Navigation Links
Spero Therapeutics Acquires Next Generation Antibacterial Candidates from Pro Bono Bio for Treatment of Multidrug-Resistant, Gram-Negative Infections
Date:1/31/2017

CAMBRIDGE, Mass., Jan. 31, 2017 /PRNewswire-USNewswire/ -- Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today announced it has acquired a next generation set of antibacterial candidates from Pro Bono Bio Ltd (PBB) to bolster its pipeline addressing the increased prevalence of multi-drug resistant forms of Gram-negative bacteria.   The assets acquired have been developed by Cantab Anti Infectives Ltd, a PBB group company.

"The acquisition of these antibacterial candidates from PBB demonstrates our commitment to finding new approaches to treat multi-drug resistant bacterial infections that continue to pose a serious threat to society. We are continuing to build our pipeline of differentiated anti-infectives and are excited to have gained access to this next-generation set of candidates for further study," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero.

Michael Earl, Chief Operating Officer of PBB, added "We believe that the antibacterial candidates discovered by Cantab have the potential to provide novel, safer alternatives to treat serious Gram-negative infections. We are pleased to transition the program to the highly experienced team at Spero Therapeutics who possesses the specific know how needed to bring the program through pre-clinical and clinical stages of development in this therapy area."

Spero will continue to work collaboratively with Cantab to develop the acquired antibacterial compounds for treatment of multi-drug resistant strains of serious Gram-negative pathogens such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Under the terms of the agreement, Spero will receive all intellectual property associated with Cantab's program in exchange for undisclosed upfront and milestone payments, as well as royalties upon commercialization of any therapeutic candidates. 

The Cantab program is currently substantially funded by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, through contract HHSN272201500014C, which is being used to evaluate the potential of these candidate compounds against certain Gram-negative Category A and B pathogens NIAID has identified as possible diseases of public health concern.  

About Spero

Spero Therapeutics is a global multi-asset clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to developing a novel and highly differentiated pipeline of antibacterials focused on unmet needs of patients with drug resistant bacterial infections.  Spero Therapeutics is advancing two lead programs in parallel, SPR741 and SPR994.  SPR741, also called Potentiator, is a platform approach to combination therapy to treat serious and life-threatening multi-drug resistant gram negative infections, such as Enterobacteriaceae and Acinetobacter baumanii, including carbapenem resistant strains.  SPR741 increases the spectrum and potency of more than two dozen classes of gram positive antibiotics to include activity against multidrug resistant gram negative infections when used in combination.  SPR994 is a novel oral agent that has demonstrated potent invitro activity against a wide variety of gram-negative bacteria, including extended spectrum beta lactamases (ESBLs), and gram-positive bacteria.  Spero Therapeutics also has a robust preclinical pipeline including SPR720, which is a preclinical oral asset for nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic fatal infection.  In addition, Spero Therapeutics has a variety of other discovery antimicrobials focused on drug-resistant infections. 

For more information, please visit https://sperotherapeutics.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spero-therapeutics-acquires-next-generation-antibacterial-candidates-from-pro-bono-bio-for-treatment-of-multidrug-resistant-gram-negative-infections-300398954.html


'/>"/>
SOURCE Spero Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Drug development venture links translational research, business to launch new therapeutics
2. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
3. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
4. Natura Therapeutics product shown to improve decision making skills in older adults
5. Emerging class of therapeutics represents a coming wave for developers and manufacturers
6. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
7. Next-generation glaucoma therapeutics hold considerable promise
8. Nanomerics, UCL, H Lundbeck & Exeter University to research new brain therapeutics
9. Industry group release testing recommendations for oligonucleotide-based therapeutics
10. Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
11. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
Breaking Biology Technology: